Hematologic Malignancies Articles

MRD, Genetic Classification Provide More Accurate Risk Stratification in Pediatric ALL
Investigators working in the UK and Europe found a correlation between minimal residual disease kinetics and risk for relapse in pediatric patients with acute lymphoblastic leukemia.
FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.
FDA Approves Frontline Obinutuzumab for Follicular Lymphoma
The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma.
CAR T-Cell Therapy Approval Starts New Path in Childhood Leukemia
Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.
Acalabrutinib MCL Approval Raises Sequencing Questions
Owen A. O'Connor, MD, PhD, discussed the utilization of acalabrutinib (Calquence), how it sequences with other approved therapies, and the promise for chimeric antigen receptor T-cell therapy in mantle cell lymphoma.
Brentuximab Vedotin Nears European Approval for CTCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin (Adcetris) in adults with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
Umbralisib, Ublituximab, Ibrutinib Triplet Reaches 100% Response in CLL
Loretta J. Nastoupil, MD, discusses the study of the triplet of ublituximab, umbralisib (TGR-1202) and ibrutinib in CLL. 
Acalabrutinib Among Exciting Options Emerging in CLL
Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.
FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML
The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
FDA Approves Brentuximab Vedotin for CTCL
The FDA has approved brentuximab vedotin (Adcetris) as a treatment for patients with cutaneous T-cell lymphoma who have received prior systemic therapy.
Publication Bottom Border
Border Publication